LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 801–900 of 1,004
MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Auffinger, B., Thaçi, B., Ahmed, A., Ulasov, I. V., & Lesniak, M. S. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040006 · Cited by 34
Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer
Sempere, L. F. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.69 · Cited by 37
Therapeutic Use of MicroRNAs in Myocardial Diseases
Latronico, M. V. G., & Condorelli, G. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-011-0068-2 · Cited by 39
Cyclin E Transgenic Mice: Discovery Tools for Lung Cancer Biology, Therapy, and Prevention
Freemantle, S., & Dmitrovsky, E. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0297 · Cited by 37
“31 is currently under study in these models (38).”
BackgroundSeth, D., Daly, A. K., Haber, P., & Day, C. P. (2010) · Hepatology · doi:10.1002/hep.23606 · Cited by 37
Endothelial miRNAs as Cellular Messengers in Cardiometabolic Diseases
Njock, M., & Fish, J. E. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.009 · Cited by 40
AAV-mediated miRNA Delivery and Therapeutics
Xie, J., Burt, D. R., & Gao, G. (2015) · Seminars in liver disease (Print) · doi:10.1055/s-0034-1397352 · Cited by 36
Stimulation of ribosomal frameshifting by antisense LNA
Yu, C.-H., Noteborn, M., & Olsthoorn, R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq650 · Cited by 36
Micromanipulating cancer: microRNA-based therapeutics?
Petrocca, F., & Lieberman, J. (2009) · RNA Biology · doi:10.4161/rna.6.3.9013 · Cited by 36
Liu, S., Wu, Z., Guo, S., Meng, X., & Chang, X. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.11.048 · Cited by 42
Advances in miR-132-Based Biomarker and Therapeutic Potential in the Cardiovascular System
Xu, K., Chen, C., Wu, Y., Wu, M., & Lin, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751487 · Cited by 41
A Functional Screen Identifies miRs That Induce Radioresistance in Glioblastomas
Moskwa, P., Zinn, P. O., Choi, Y. E., Shukla, S. A., Fendler, W. M., Chen, C. C., Lü, J., Golub, T. R., Hjelmeland, A. B., & Chowdhury, D. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0268 · Cited by 37
Shimizu, K., Sakurai, F., Tomita, K., Nagamoto, Y., Nakamura, S.-I., Katayama, K., Tachibana, M., Kawabata, K., & Mizuguchi, H. (2014) · Molecular Therapy: Methods & Clinical Development · doi:10.1038/mtm.2014.35 · Cited by 35
MicroRNA-targeting therapeutics for hepatitis C
Baek, J., Kang, S., & Min, H. (2014) · Archives of pharmacal research · doi:10.1007/s12272-013-0318-9 · Cited by 35
Towards microRNA-based therapeutics for diabetic nephropathy
Alvarez, M. L., & DiStefano, J. (2013) · Diabetologia · doi:10.1007/s00125-012-2768-x · Cited by 35
“A significant decrease in the levels of miR-122 in liver, as well as a parallel increase in the expression of its target gene, Aldoa, were observed in a dose-dependent manner 48 h following the last injection with LNA antimiR-122, whereas no effect was detected in mice treated with antagomirs [59].”
BackgroundInfluentialPotential of Anti‐Cancer Therapy Based on Anti‐miR‐155 Oligonucleotides in Glioma and Brain Tumours
Poltronieri, P., D’Urso, P. I., Mezzolla, V., & D’Urso, O. F. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12002 · Cited by 38
Non-Coding RNAs as Therapeutic Targets in Hepatocellular Cancer
Braconi, C., & Patel, T. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912803987904 · Cited by 35
“No collateral effects were noted in primates, with the exception of transient alteration of creatinine phosphokinase, aminotransferases and bilirubin in those animals who underwent liver biopsies [42].”
BackgroundMicroRNAs as newer therapeutic targets: A big hope from a tiny player
Ghelani, H., Rachchh, M., & Gokani, R. H. (2012) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.99416 · Cited by 38
“The mechanisms responsible for these effects are unclear, but a preliminary study suggests that phosphatase and tensin homology deleted on chromosome 10 (PTEN) and Bcl-2 might be involved.[24] The role of miRNAs in cardiac development has been well described in several studies.”
BackgroundRole of miR-155 in breast cancer
Wang, J., & Wu, J. (2012) · Frontiers in bioscience · doi:10.2741/4056 · Cited by 38
Kuhlmann, J., Rasch, J., Wimberger, P., & Kasimir-Bauer, S. (2012) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm-2011-0847 · Cited by 35
“LNA molecules directed against miRNA122, a miRNA involved in cholesterol and lipid metabolism (125) , were intravenously injected into African green monkeys and caused a durable decrease in plasma cholesterol (121) .”
BackgroundMethodPost-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease.
Kaucsár, T., Rácz, Z., & Hamar, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.003 · Cited by 35
The etiological roles of miRNAs , lncRNAs , and circRNAs in neuropathic pain: A narrative review
Jiang, M. H., Wang, Y., Wang, J., Feng, S., & Wang, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24592 · Cited by 40
MicroRNA regulation of cholesterol metabolism
Citrin, K. M., Fernandez-Hernando, C. F., & Suárez, Y. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14566 · Cited by 48
Hendy, O. M., Rabie, H., Fouly, A. E., Abdel‐Samiee, M., Abdelmotelb, N., Elshormilisy, A. A., Allam, M., Ali, S. T., Mohamed, N. M. B. E. D., Abdelsattar, S., et al. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s231321 · Cited by 39
“Therefore, the mi-RNA-122 has been suggested as a possible therapeutic target in the treatment of hypercholesterolemia in humans.(40) On the contrary, Cheung et al.”
BackgroundRNA regulatory processes in RNA virus biology
Cross, S. T., Michalski, D., Miller, M. R., & Wilusz, J. (2019) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1536 · Cited by 46
“A miR-122 antagonist effectively inhibits HCV replication, and is currently being evaluated as a novel antiviral therapeutic (Elmén, Lindow, et al., 2008; Lindow, Silahtaroglu, et al., 2008; Ottosen et al., 2015) .”
BackgroundGiovannini, C., Fornari, F., Dallo, R., Gagliardi, M., Nipoti, E., Vasuri, F., Coadǎ, C. A., Ravaioli, M., Bolondi, L., & Gramantieri, L. (2017) · Acta Histochemica · doi:10.1016/j.acthis.2017.12.004 · Cited by 31
“…of their physiologic nature, miRNA-based gene therapies showed a long-lasting effect in presence of a safety profile and very low toxicity (Callegari et al., 2013; Callegari et al., 2012; Elmen et al., 2008; Kota et al., 2009; Krutzfeldt et al., 2005; Janssen et al., 2013; Ling et al., 2013).”
Characterization of miR-122-independent propagation of HCV
Ono, C., Fukuhara, T., Motooka, D., Nakamura, S., Okuzaki, D., Yamamoto, S., Tamura, T., Mori, H., Sato, A., Uemura, K., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006374 · Cited by 34
TP53/MicroRNA Interplay in Hepatocellular Carcinoma
Pollutri, D., Gramantieri, L., Bolondi, L., & Fornari, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122029 · Cited by 41
“In the last decade, several studies have demonstrated the efficacy and non-toxicity of chemically-modified oligonucleotides in preclinical animal models [46,83] and recently a phase 2a clinical trial reported the efficacy of an antimiRNA-122-mediated drug (Miravirsen) for the treatment of HCV-infected patients [48].”
BackgroundMiR-21 is required for efficient kidney regeneration in fish
Hoppe, B., Pietsch, S., Franke, M., Engel, S., Groth, M., Platzer, M., & Englert, C. (2015) · BMC Developmental Biology · doi:10.1186/s12861-015-0089-2 · Cited by 43
“These stabilized RNA-oligonucleotides have been shown to bind specifically to their target miRNA and prevent them from binding to their respective mRNA targets [23, 24].”
BackgroundPotent inhibition of miR-27a by neomycin–bisbenzimidazole conjugates
Nahar, S., Ranjan, N., Ray, A., Arya, D., & Maiti, S. (2015) · Chemical Science · doi:10.1039/c5sc01969a · Cited by 34
Figueira, M. F., Monnerat, G., Medei, E. H., Carvalho, A. B., Morales, M. M., Lamas, M., da Fonseca, R. N., & Souza‐Menezes, J. (2014) · Acta Physiologica · doi:10.1111/apha.12316 · Cited by 30
The new concepts on overcoming drug resistance in lung cancer
Dong, X., Xu, C., Lei, P., & Zhang, W. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s60672 · Cited by 32
“As an example, locked nucleic acid (LNA) miRNA derivatives represent a class of chemically modified nucleic acids that inhibit specific miRNAs in mouse models(65) and in nonhuman primates.(66) LNAs and related compounds are designed to be stable in serum and to exert limited off-target toxicities.”
BackgroundThibault, P. A., & Wilson, J. A. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.004 · Cited by 37
Mehta, M., Satija, S., Paudel, K. R., Malyla, V., Kannaujiya, V. K., Chellappan, D. K., Bebawy, M., Hansbro, P. M., Wich, P. R., & Dua, K. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102303 · Cited by 36
MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury
Markovic, J., Sharma, A. D., & Balakrishnan, A. (2020) · Cells · doi:10.3390/cells9081767 · Cited by 42
“LNA-antimiRs are antisense RNAs in which usually every third nucleotide has a modified ribose moiety, and which possess a much higher hybridization affinity and stability in miRNA-LNA-antimiR duplexes than traditional probes [47].”
BackgroundEmerging microRNA Therapeutic Approaches for Cystic Fibrosis
Bardin, P., Sonneville, F., Corvol, H., & Tabary, O. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01113 · Cited by 46
Therapeutic prospects of microRNAs in cancer treatment through nanotechnology
Awasthi, R., Rathbone, M. J., Hansbro, P. M., Bebawy, M., & Dua, K. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0440-1 · Cited by 38
Introduction of 2,6‐Diaminopurines into Serinol Nucleic Acid Improves Anti‐miRNA Performance
Kamiya, Y., Donoshita, Y., Kamimoto, H., Murayama, K., Ariyoshi, J., & Asanuma, H. (2017) · ChemBioChem · doi:10.1002/cbic.201700272 · Cited by 33
MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy
Pourshafie, N., Lee, P. R., Chen, K.-L., Harmison, G. G., Bott, L. C., Katsuno, M., Sobue, G., Burnett, B. G., Fischbeck, K., & Rinaldi, C. (2016) · Molecular Therapy · doi:10.1038/mt.2016.13 · Cited by 33
Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy
Aaldering, L. J., Tayeb, H. H., Krishnan, S., Fletcher, S., Wilton, S., & Veedu, R. N. (2015) · RNA Biology · doi:10.1080/15476286.2015.1017234 · Cited by 33
“demonstrated the function of LNA-modified antimiRs in vivo, demonstrating antimiRs as an important therapeutic tool.(102) In 2012, Kim et al.”
Backgroundcis-Acting RNA elements in the hepatitis C virus RNA genome
Sagan, S. M., Chahal, J., & Sarnow, P. (2015) · Virus Research · doi:10.1016/j.virusres.2014.12.029 · Cited by 45
Self-citationNon-Coding RNAs and Lipid Metabolism
Smolle, E., & Haybaeck, J. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150813494 · Cited by 32
“miR-122 was also found to influence lipid metabolism, since anti-miR-122 therapy reduced cholesterol levels in mice and primates significantly [45,60,61].”
BackgroundCondon, D. E., Yildirim, I., Kennedy, S. D., Mort, B. C., Kierzek, R., & Turner, D. (2013) · Journal of Physical Chemistry B · doi:10.1021/jp408909t · Cited by 33
Song, S. J., & Pandolfi, P. P. (2013) · Cell Cycle · doi:10.4161/cc.27027 · Cited by 32
Delivery of RNAi therapeutics: work in progress
Miller, A. D. (2013) · Expert Review of Medical Devices · doi:10.1586/17434440.2013.855471 · Cited by 33
Mechanisms generating bistability and oscillations in microRNA-mediated motifs
Zhou, P., Cai, S., Liu, Z., & Wang, R. (2012) · Physical Review E · doi:10.1103/physreve.85.041916 · Cited by 37
MiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer?
Zárate, R., Boni, V., Bandrés, E., & García‐Foncillas, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13010840 · Cited by 32
“AMOs are chemically modified in a variety of ways, such as with locked nucleic acid (LNA) [119], 2'-O-methyl- [120], and 2'-O-methoxyethyl-modified (2'-MOE) oligonucleotides [121], to improve their stability and to reduce their degradation.”
BackgroundBerezhna, S. Y., Supeková, Ľ., Sever, M. J., Schultz, P. G., & Deniz, A. A. (2011) · RNA · doi:10.1261/rna.2523911 · Cited by 35
“In normal biology of liver cells, miRNA-122 was reported to regulate the mevalonate pathway and expression of genes involved in hepatic lipids and cholesterol metabolism (Krutzfeldt et al. 2005; Esau et al. 2006; Elmen et al. 2008; Norman and Sarnow 2010).”
BackgroundStrategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Abifadel, M., Pakradouni, J., Collin, M., Bouma, M. E., Varret, M., Rabès, J., & Boileau, C. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.518615 · Cited by 34
“Such molecules have been shown to potently and safely inhibit both mRNA and micro-RNA (miRNA) targets in mouse [65] and non-human primate [66,67] models, and several different LNA drugs are currently in clinical trials against cancer and infectious diseases [67-69].”
BackgroundClinical Applications of Mirnas in Cardiac Remodeling and Heart Failure
Topkara, V. K., & Mann, D. L. (2010) · Personalized Medicine · doi:10.2217/pme.10.44 · Cited by 32
Biogenesis and function of endogenous and exogenous siRNAs
Snead, N. M., & Rossi, J. J. (2010) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.14 · Cited by 42
Non-coding RNAs for medical practice in oncology.
Setoyama, T., Hui, L., Natsugoe, S., & Calin, G. (2011) · The Keio Journal of Medicine · doi:10.2302/kjm.60.106 · Cited by 33
Exploiting the Therapeutic Potential of MicroRNAs in Viral Diseases: Expectations and Limitations
Hemida, M. G., Ye, X., Thair, S., & Yang, D. (2010) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256383 · Cited by 32
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
Vanin1 (VNN1) in chronic diseases: Future directions for targeted therapy.
Yu, H., Cui, Y., Guo, F.-Y., Zhu, Y.-T., Zhang, X.-N., Shang, D., Dong, D.-S., & Xiang, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176220 · Cited by 32
Yu, Y., Liao, L., Shao, B.-Y., Su, X., Shuai, Y., Wang, H., Shang, F.-Q., Zhou, Z.-F., Yang, D.-Q., & Jin, Y. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.017 · Cited by 32
Noncoding RNAs in tumor metastasis: molecular and clinical perspectives
Liu, Q.-L., Zhang, Z., Wei, X., & Zhou, Z. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03929-0 · Cited by 48
Bioengineering Technologies for Cardiac Regenerative Medicine
Chingale, M., Zhu, D., Cheng, K., & Huang, K. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.681705 · Cited by 39
microRNAs as therapeutic targets in intestinal diseases
Wang, C., & Chen, J. (2019) · ExRNA · doi:10.1186/s41544-019-0026-9 · Cited by 33
MicroRNAs in Animal Models of HCC
Fornari, F., Gramantieri, L., Callegari, E., Shankaraiah, R. C., Piscaglia, F., Negrini, M., & Giovannini, C. (2019) · Cancers · doi:10.3390/cancers11121906 · Cited by 37
“efficacy of chemically modified oligonucleotides targeting the liver-specific miR-122 in both rodent and nonhuman primate species [32,62].”
BackgroundBridged Nucleic Acids Reloaded
Soler‐Bistué, A., Zorreguieta, Á., & Tolmasky, M. E. (2019) · Molecules · doi:10.3390/molecules24122297 · Cited by 34
“Fortunately, recent studies showed that LNA-containing oligomers were innocuous in primates [56] and relatively safe in humans [57–59].”
BackgroundMiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells
Cola, A. D., Lamolinara, A., Lanuti, P., Rossi, C., Iezzi, M., Marchisio, M., Todaro, M., & de Laurenzi, V. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0854-9 · Cited by 32
Yu, Y.-P., Scheel, T., Luna, J., Chung, H., Nishiuchi, E., Scull, M., Echeverría, N., Ricardo-Lax, I., Kapoor, A., Lipkin, I., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006694 · Cited by 32
Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis?
Philippen, L. E., Dirkx, E., Wit, J. B. M., Burggraaf, K., Windt, L. J. D., & Martins, P. A. D. C. (2015) · Molecular Therapy · doi:10.1038/mt.2015.133 · Cited by 36
“All rights reserved At the current time, organ specific targeting of ol ig nucleotides has only shown to be successful in the liver.(43) In order to become of greater utility, effective d elivery methods to other organs, especially the heart, are absolutely required.”
BackgroundFan, B., Sutandy, F. X. R., Syu, G., Middleton, S., Yi, G., Lu, K., Chen, C., & Kao, C. C. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.050344 · Cited by 38
Oligomeric Nucleic Acids as Antivirals
Mescalchin, A., & Restle, T. (2011) · Molecules · doi:10.3390/molecules16021271 · Cited by 32
“A miR-122 inhibitor (SPC3649) was developed with an optimized combination of LNA and DNA bases and a PS backbone [84] which led to specific and stabile down-”
BackgroundSmall RNA Regulators of T Cell-Mediated Autoimmunity
Jeker, L. T., & Bluestone, J. A. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9392-7 · Cited by 30
“Experimental data suggest that small RNA-based therapeutics can be extremely challenging but powerful [135–138].”
BackgroundHao, P., & Waxman, D. J. (2018) · Endocrinology · doi:10.1210/en.2017-03109 · Cited by 31
Hromadníková, I., Kotlabová, K., & Krofta, L. (2022) · Biomedicines · doi:10.3390/biomedicines10030718 · Cited by 37
Social status affects lipid metabolism in rainbow trout,Oncorhynchus mykiss
Kostyniuk, D. J., Culbert, B. M., Mennigen, J. A., & Gilmour, K. M. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00402.2017 · Cited by 37
“Liver-specific miRNA122 has been shown to stimulate serum triglyceride and cholesterol concentrations in rainbow trout (56), in line with previously reported roles in mammals (24, 25).”
BackgroundMicroRNA-122a Regulates Zonulin by Targeting EGFR in Intestinal Epithelial Dysfunction
Zhang, B., Tian, Y., Jiang, P., Jiang, Y.-Q., Li, C., Liu, T., Zhou, R., Yang, N., Zhou, X.-K., & Liu, Z.-H. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478629 · Cited by 31
Epigenetic aspects of rheumatoid arthritis: contribution of non-coding RNAs
Kolarz, B., & Majdan, M. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.01.003 · Cited by 35
Samir, M., & Peßler, F. (2016) · Frontiers in Veterinary Science · doi:10.3389/fvets.2016.00022 · Cited by 31
Nanoparticle delivery of miR-223 to attenuate macrophage fusion
Moore, L. B., Sawyer, A. J., Saucier-Sawyer, J. K., Saltzman, W. M., & Kyriakides, T. R. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.036 · Cited by 34
“Mir-based approaches to treat various conditions have been described [27-30].”
Murayama, K., Kashida, H., & Asanuma, H. (2015) · Chemical Communications · doi:10.1039/c4cc09244a · Cited by 31
The Potential of MicroRNAs in Personalized Medicine against Cancers
Saumet, A., Mathelier, A., & Lecellier, C. (2014) · BioMed Research International · doi:10.1155/2014/642916 · Cited by 32
“LNA-mediated miRNA silencing was shown to be efficient in vivo even in non-human primates [141].”
BackgroundSibley, C. R., & Wood, M. J. A. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0781-z · Cited by 28
Apoptosis in Carcinogenesis and Chemotherapy
Chen, G. G., & Lai, P. B. S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9597-9 · Cited by 60
Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers
Abdi, E., Latifi‐Navid, S., Abdi, F. S., & Taherian‐Esfahani, Z. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1842199 · Cited by 36
Current role of non-coding RNAs in the clinical setting
Vicentini, C., Galuppini, F., Corbo, V., & Fassan, M. (2019) · Non-coding RNA Research · doi:10.1016/j.ncrna.2019.09.001 · Cited by 30
Loss of Hepatic Oscillatory Fed microRNAs Abrogates Refed Transition and Causes Liver Dysfunctions
Maniyadath, B., Chattopadhyay, T., Verma, S. P., Kumari, S., Kulkarni, P., Banerjee, K. K., Lazarus, A., Kokane, S. S., Shetty, T., Anamika, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.087 · Cited by 30
Genetic and Epigenetic Culprits in the Pathogenesis of Nonalcoholic Fatty Liver Disease
Kovalic, A. J., Banerjee, P., Tran, Q. T., Singal, A. K., & Satapathy, S. K. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.04.001 · Cited by 34
“Presently, the most highly touted entity of this group has been miR-122, which constitutes over 70% of hepatic miRNA expression.(89) One of its primary targets serves to decrease the expression of numerous genes critical for lipid metabolism, such as FASN, ACC2, SCD1, and ACLY.”
BackgroundUnlocked Nucleic Acids for miRNA detection using two dimensional nano-graphene oxide.
Robertson, N. M., Toscano, A. E., LaMantia, V. E., Hizir, M., Rana, M., Balcioğlu, M., Sheng, J., & Yigit, M. (2017) · Biosensors & bioelectronics · doi:10.1016/j.bios.2016.02.058 · Cited by 30
Macrophage miRNAs in atherosclerosis
Karunakaran, D., & Rayner, K. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.006 · Cited by 29
Correlation between down-expression of miR-431 and clinicopathological significance in HCC tissues
Pan, L.-J., Ren, F., Rong, M.-H., Dang, Y.-W., Luo, Y., Luo, D., & Chen, G. (2015) · Clinical and Translational Oncology · doi:10.1007/s12094-015-1278-y · Cited by 30
miRNAs in inflammatory skin diseases and their clinical implications
Løvendorf, M. B., & Skov, L. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1020301 · Cited by 31
“conducted a pioneering study demonstrating the use of systemically administered locked nucleic acid (LNA) anti-miRs in non-human primates [24].”
BackgroundHsu, S.-H., Wang, B., Kutay, H., Bid, H., Shreve, J., Zhang, X.-L., Costinean, S., Bratasz, A., Houghton, P., & Ghoshal, K. (2013) · American Journal of Pathology · doi:10.1016/j.ajpath.2013.08.004 · Cited by 30
Karolina, D. S., Armugam, A., Sepramaniam, S., & Jeyaseelan, K. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.21 · Cited by 29
Functional Studies of microRNAs in Neural Stem Cells: Problems and Perspectives
Åkerblom, M., Sachdeva, R., & Jakobsson, J. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00014 · Cited by 31
Cheng, G., & Jin, Y. (2012) · Parasitology · doi:10.1017/s0031182011001855 · Cited by 36
Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer—A review
Dhayat, S. A., Mardin, W. A., Mees, S. T., & Haier, J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26078 · Cited by 33
siRNAs: Potential therapeutic agents against Hepatitis C Virus
Ashfaq, U. A., Yousaf, M., Aslam, M., Ejaz, R., Jahan, S., & Ullah, O. (2011) · Virology Journal · doi:10.1186/1743-422x-8-276 · Cited by 30
Promise and challenge of RNA interference-based therapy for cancer.
Petrocca, F., & Lieberman, J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6287 · Cited by 30
Usman, M., Nakasa, T., Shoji, T., Kato, T., Kawanishi, Y., Hamanishi, M., Kamei, N., & Ochi, M. (2015) · Journal of Orthopaedic Science · doi:10.1007/s00776-015-0709-5 · Cited by 30
MicroRNAs and Lipoprotein Metabolism
Horie, T., Baba, O., Kuwabara, Y., Yokode, M., Kita, T., Kimura, T., & Ono, K. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.20859 · Cited by 29
MicroRNA: Potential biomarker and target of therapy in acute lung injury
Jiang, Z.-F., Zhang, L., & Shen, J. (2020) · Human and Experimental Toxicology · doi:10.1177/0960327120926254 · Cited by 29
“Locked nucleic acid (LNA) which is an unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide improves binding affinity, nucleic resistance, and thus effectively inhibits miRNA in mice and nonhuman primates.(139,140) Short seed-targeting LNA oligonucleotides (also called tiny LNAs) are 7– 8 nucleotid…”
BackgroundThe noncoding-RNA landscape in cardiovascular health and disease
Mauro, V. D., Barandalla-Sobrados, M., & Catalucci, D. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.02.001 · Cited by 29
Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis
Zhou, L., & Hussain, M. M. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309247 · Cited by 35
Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis
Kim, H. S., Shen, Q., & Nam, S. (2015) · Journal of Korean medical science · doi:10.3346/jkms.2015.30.10.1375 · Cited by 29
“showed simple systemic delivery of anti-miR and effectively antagonized liver-expressed miR-122, a tumor suppressive microRNA, in non-human primates without toxicity (41).”
Nonconventional chemical inhibitors of microRNA: therapeutic scope
Jayaraj, G. G., Nahar, S., & Maiti, S. (2014) · Chemical Communications · doi:10.1039/c4cc04514a · Cited by 35
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.